



October 28, 2026

Company: KYORIN Pharmaceutical Co., Ltd.
Representative: Yutaka Ogihara
Representative Director, President and CEO
(Security Code: 4569, TSE Prime.)
Contact: Shota Kikuchi
Director, Corporate Planning
Telephone: 03-6374-9702

Notice Concerning Change in Major Shareholder

KYORIN Pharmaceutical Co., Ltd. (the “Company”) announces today that there has been a change in a major shareholder of the Company as of October 15, 2026, as described below.

1. Background of the change

On October 27, 2026, the shareholder listed below submitted the Large Shareholding Report (Amendment Report) to the Director-General of the Kanto Local Finance Bureau, and the Company has confirmed the change in its major shareholder.

2. Overview of the shareholder subject to the change

(1) Name	Kopernik Global Investors, LLC
(2) Location	251 Little Falls Drive, City of Wilmington, Delaware 19808, U.S.A
(3) Job title and name of representative	General Counsel and Chief Compliance Officer, Sarah L. Bertrand
(4) Description of business	Investment management business

3. Number of voting rights (number of shares) held by said shareholder and its ratio to the voting rights held by all shareholders before and after the change

	Number of voting rights (Number of shares held)	Ratio of voting rights held*
Before the change (As of April 30, 2026)	52,428 units (5,242,800 shares)	9.04%
After the change (As of October 15, 2026)	60,512 units (6,051,200 shares)	10.44%

1) The above is based on the Large Shareholding Report (Amendment Report) submitted by the relevant shareholder, and the Company has not been able to confirm the actual number of shares beneficially owned or the number of voting rights held by the relevant shareholder. In addition, the ranking of major shareholders has not been confirmed, so it is not stated.

2) The “Ratio of voting rights held” is truncated to two decimal places.

(Before the change) Calculated as a percentage of the total number of voting rights of all shareholders (579,678 units, representing 57,967,800 shares) after deducting the number of shares without voting rights as of March 31, 2026 (1,977,841 shares), from the total number of issued shares as of the same date (59,945,641 shares).

(After the change) Calculated as a percentage of the total number of voting rights of all shareholders (579,605 units, representing 57,960,500 shares) after deducting the number of shares without voting rights as of September 30, 2026 (1,985,141 shares), from the total number of issued shares as of the same date (59,945,641 shares).

4. Future outlook

This matter is based on the Large Shareholding Report (Amendment Report) and there are no particular matters to be disclosed regarding the Company’s future outlook.